Supplier: ProMab Technologies
Type of Product: Monoclonal Antibody
Description: Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle.
Application: ELISA: 1/10000; WB: 1/500 - 1/2000; IHC: 1/200 - 1/1000; FCM: 1/200 - 1/400
Size: 100 ul, 1mg/ml
Species Reactivity: Human
Isotype: Mouse IgG1
Immunogen: Purified recombinant fragment of human ApoE expressed in E. Coli. ;
Formulation: Ascitic fluid containing 0.03% sodium azide.
Storage: 4C; -20C for long term storage
Spplier link: http://www.promab.com/index.php?main_page=product_info&products_id=614
Reference: 1. Arch Dermatol Res. 2009 Jul;301(6):405-10. ; 2. Pharmacogenomics J. 2009 Aug;9(4):248-57.